K-BOOSTNCT07622017
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 46 words
- Start date changed from estimate of Jul 2026 to Oct 5, 2026
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
Participants receive intratumoral KRC-01 injections (8 injections) combined with standard long-course chemoradiotherapy (radiotherapy: 50 Gy in 25 fractions plus capecitabine 825 mg/m² orally twice daily for 5 weeks) and consolidation chemotherapy with CAPOX or FOLFOX according to investigator decision and institutional practice. Surgery with total mesorectal excision (TME) may be performed depending on tumor response and multidisciplinary team assessment.
Drugs: KRC-01 (KORTUC), Capecitabine, CAPOX, FOLFOX
Radiation: Radiotherapy
Procedures: Optionnal TME
Sites
2 sites in 1 country